

InnoCan Pharma

14:00 26 Jun 2020

InnoCan Pharma demonstrates safety and skin tolerance of its CBD skin products

InnoCan Pharma Corporation (CSE:INNO) revealed Friday that it was in advanced negotiations with distributors in Switzerland, Germany, the UK, Hong Kong and the United States as the company announced positive findings from the first dermal clinical study of Relief & Go and Shir product lines.

The pharmaceutical tech group has developed several lines of skin cosmetic products containing a blend of highly concentrated ingredients formulated with CBD. It said it is eyeing first samples shipments in July this year.

READ: InnoCan Pharma inks deal securing CBD for its coronavirus treatment collaboration with Tel Aviv University and other R&D projects

"The double blinded randomized controlled study assessed the tolerance degree of the company's CBD Topicals products and demonstrated the products to be non-irritating to the skin," the firm said in a statement.

InnoCan's contract manufacturer for these products Fancystage is in an advanced production stage with InnoCan's first derma cosmetic products launch, it added.

"This clinical investigation was performed in accordance with the respective Clinical Investigation Plan (CIP) and was consistent with the main principles of ICH GCP, Helsinki declaration. The results of this study demonstrated the safety and skin tolerance of the InnoCan's CBD Derma Cosmetic Line of products," said Nir Avram, InnoCan's chief technology officer (CTO).

"We've developed our products through our leading cannabinoid research labs in Israel," said Iris Bincovich, co-founder and CEO of InnoCan Pharma.

"We believe that our approach to manufacturing high quality products in a state-of-the-art facility that has all the necessary certifications will open us up to a multi billion EURO market."

Shares in Toronto advanced over 14% to C\$0.16 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Price: 0.18

Market Cap: \$31.56 m

1 Year Share Price Graph



Share Information

Code: INNO

Listing: CSE

52 week	High	Low
	0.4	0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).